霍奇金淋巴瘤:2018年诊断、风险分层与管理更新
霍奇金淋巴瘤(HL)是一种少见的B细胞淋巴样恶性肿瘤,美国每年新发8500例,约占所有淋巴瘤的10.2%。本文更新了HL的诊断分类、风险分层(基于分期、预后模型和PET扫描反应)、风险适应性治疗(早期联合模式、晚期化疗、新药整合)以及复发/难治性疾病的管理(HDCT+ASCT为标准,失败后考虑brentuximab vedotin、PD-1阻断、非清髓性异基因移植或临床试验)。
要点
- HL分为经典型HL和结节性淋巴细胞为主型HL,经典型包括结节硬化型、混合细胞型、淋巴细胞消减型和富淋巴细胞型。
- 准确分期是选择适当治疗的关键,预后模型和PET扫描确定的治疗反应用于优化治疗。
- 复发/难治患者中,HDCT后ASCT是大多数患者的标准治疗;ASCT失败后可考虑brentuximab vedotin、PD-1阻断、非清髓性异基因移植或临床试验。
核心结论
- HL的诊断、风险分层和治疗需基于组织学、解剖分期和不良预后特征;风险适应性治疗和新药整合正在成为标准。
研究设计与样本
- 本文为综述,检索范围未报告。
主要发现
- HL在美国每年新发8500例,约占所有淋巴瘤的10.2%。
- HL分为经典型HL和结节性淋巴细胞为主型HL;经典型HL包括结节硬化型、混合细胞型、淋巴细胞消减型和富淋巴细胞型。
- 早期患者通常接受短程联合化疗后累及野放疗的联合模式策略;晚期患者接受较长疗程化疗,通常不放疗。
- brentuximab vedotin等新药正在被纳入一线治疗,新联合方案正在成为标准治疗。
- 复发患者中,HDCT后ASCT是大多数患者的标准治疗;ASCT失败后可考虑brentuximab vedotin、PD-1阻断、非清髓性异基因移植或临床试验。
关键数值与推荐
- 准确分期是选择适当治疗的关键。
- 预后模型识别低危或高危复发患者,PET扫描确定的治疗反应用于优化治疗。
- 初始治疗基于组织学、解剖分期和不良预后特征。
- 早期患者采用短程联合化疗后累及野放疗;晚期患者接受较长疗程化疗,通常不放疗。
- 复发/难治患者:HDCT后ASCT为标准治疗;ASCT失败后考虑brentuximab vedotin、PD-1阻断、非清髓性异基因移植或临床试验。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
DISEASE OVERVIEW: Hodgkin lymphoma (HL) is an uncommon B-cell lymphoid malignancy affecting 8500 new patients annually and representing approximately 10.2% of all lymphomas in the United States. DIAGNOSIS: HL is composed of two distinct disease entities: classical HL and nodular lymphocyte predominant HL. Nodular sclerosis, mixed cellularity, lymphocyte depletion, and lymphocyte-rich HL are subgroups of classical HL. RISK STRATIFICATION: An accurate assessment of the stage of disease in patients with HL is critical for the selection of the appropriate therapy. Prognostic models that identify patients at low or high risk for recurrence, as well as the response to therapy as determined by positron emission tomography scan, are used to optimize therapy. RISK-ADAPTED THERAPY: Initial therapy for HL patients is based on the histology of the disease, the anatomical stage and the presence of poor prognostic features. Patients with early stage disease are typically treated with combined modality strategies utilizing abbreviated courses of combination chemotherapy followed by involved-field radiation therapy, while those with advanced stage disease receive a longer course of chemotherapy often without radiation therapy. Newer agents including brentuximab vedotin are now being incorporated into frontline therapy and these new combinations are becoming a standard of care. MANAGEMENT OF RELAPSED/REFRACTORY DISEASE: High-dose chemotherapy (HDCT) followed by an autologous stem cell transplant (ASCT) is the standard of care for most patients who relapse following initial therapy. For patients who fail HDCT with ASCT, brentuximab vedotin, PD-1 blockade, nonmyeloablative allogeneic transplant or participation in a clinical trial should be considered.
引用
- Ansell SM. Hodgkin lymphoma: 2018 update on diagnosis, risk-stratification, and management. Am J Hematol. 2018. PMID: 29634090. doi:10.1002/ajh.25071
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。